| ORIGINAL ARTICLES |
|
|
|
|
|
Screening, Characterization and Evaluation of Mangiferin Polymorphs |
| Shiying Yang1, Qi Zhou1, Baoxi Zhang1, Li Zhang1, Dezhi Yang1, Haiguang Yang2, Guanhua Du2, Yang Lu1 |
1 Beijing Key Laboratory of Polymorphic Drugs, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China;
2 Beijing Key Laboratory of Drug Targets and Screening Research, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China |
|
|
|
|
Abstract Mangiferin is a compound with many pharmacological activities and exists in many natural products. Anhydrous and hydrate of mangiferin have been reported separately in two literatures, but the polymorphism of this compound has not been realized until this paper. In this study, polymorph screening of mangiferin has been carried out and five forms have been obtained including three new forms never reported. Several solid state characterization methods, such as powder X-ray diffraction, differential scanning calorimetry and thermogravimetry, are used to identify and characterize all of mangiferin forms. The comparison of the crystallographic data and hirshfeld surface analysis were first reported for mangiferin anhydrous and hydrate. Furthermore, the studies on stability, transformation and solubility have been undertaken, the results prompt that form V can be used as the dominant polymorph for the development of innovative pharmaceuticals.
|
| Keywords
Mangiferin
Polymorph screening
Characterize
Stability
Solubility
|
| Fund:The authors thank the financial support from Key National Research and Development Programmes (Grant No.2016YFC1000905), the Drug Innovation Major Project (Grant No. 2018ZX09711001-001-013), the National Natural Science Foundation of China (Grant No. 81703473), the Drug Innovation Major Project (Grant No. 2018ZX09711001-010, 2017ZX09101001003), and CAMS Innovation Found for Medical Sciences (Grant No. 2016-I2M-1-007). |
|
Corresponding Authors:
Guanhua Du, Yang Lu
E-mail: dugh@imm.ac.cn;luy@imm.ac.cn
|
|
Issue Date: 19 August 2020
|
|
|
1. P. Jyotshna, K. Khare, Shanker. BioFactors 42, 504-514 (2016)
2. T. Ehianeta, S. Laval, B. Yu, BioFactors 42, 445-458 (2016)
3. S. Iseda, Bull. Chem. Soc. Jpn. 30, 629-633 (1957)
4. P.E. Nott, J.C. Roberts, Phytochemistry 6, 1597-1599 (1967)
5. V. Peres, T.J. Nagem, F.F. De Oliveira, Phytochemistry 55, 683-710 (2000)
6. I. Carpenter, H.D. Locksley, F. Scheinmann, Phytochemistry 8, 2013-2025 (1969)
7. D. Chen, R. Chen, R. Wang, J. Li, K. Xie, C. Bian, L. Sun, X. Zhang, J. Liu, L. Yang, F. Ye, X. Yu, J. Dai, Angew. Chem. 54, 12678-12682 (2015)
8. T. Sato, A. Kawamoto, A. Tamura, Y. Tatsumi, T. Fujii, Chem. Pharm. Bull. 40, 721-724 (1992)
9. P.M. Pauletti, I. Castro-Gamboa, D.H. Siqueira, I. Silva, M.C. Young, D.M. Tomazela, M.N. Eberlin, V. da SilvaBolzani, J. Nat. Prod. 66, 1384-1387 (2003)
10. Z.Q. Wei, L. Yan, J.G. Deng, J. Deng, Chin. J. Chin. Mater. Med. 13, 1798-1802 (2011)
11. H.W. Guo, J.G. Deng, C.X. Yun, G.H. Hou, J. Du, Chin. J. Exp. Trad. Med. Formul. 18, 187-190 (2012)
12. M.S. Zheng, Z.Y. Lu, Acta Pharm. Sin. 10, 85-90 (1989)
13. S.A.J. Nunez, M. Daglia, L. Rastrelli, BioFactors 42, 475-491 (2016)
14. H. Li, J. Huang, B. Yang, T. Xiang, X. Yin, W. Peng, W. Cheng, J. Wan, F. Luo, H. Li, G. Ren, Toxicol. Appl. Pharmacol. 272, 180-190 (2013)
15. G.C. Jagetia, M.S. Baliga, Phytomedicine 12, 209-215 (2005)
16. Z.P. Wang, J.G. Deng, Z.Y. Tan, Lishizhen Med. Mater. Med. Res. 20, 2167-2168 (2009)
17. X. Zhu, Y.Q. Cheng, L. Du, Y. Li, F. Zhang, H. Guo, Y.W. Liu, X.X. Yin, Phytother. Res. 29, 295-302 (2015)
18. P.S. Sellammuthu, P. Arulselvan, B.P. Muniappan, S. Fakurazi, M. Kandasamy, J. Med. Food. 16, 719-727 (2013)
19. Y. Niu, W. Lu, L. Gao, H. Lin, X. Liu, L. Li, Pharm Biol. 50, 1177-1182 (2012)
20. H.G. Yang, Q.M. Zhou, H.G. Wang, X. Cheng, X.Y. Zhao, Y. Lu, L.H. Fang, G.H. Du, Chin. Pharm. Bull. 34, 1356-1362 (2018)
21. J.Q. Wei, Z.M. Zheng, Y. Pan, J. Guangxi Med. Univ. 25, 732-733 (2008)
22. S. Muruganandan, J. Lal, P.K. Gupta, Toxicology 215, 57-68 (2005)
23. K.R. Morris, N. Rodriguez-Hornedo, in:J. Swarbrick, J. Boylan, Encyclopedia of Pharmaceutical Technology, vol. 7 (Marcel Dekker Inc., New York, 1993), pp. 393-440
24. Y. Lu, G.H. Du, Polymorphic Drugs (People's Medical Publishing House, Beijing, 2009), pp. 1-9
25. V. Lopez-Mejías, A.J. Matzger, Cryst. Growth Des. 15, 3955-3962 (2015)
26. H.G. Brittain, Polymorphism in Pharmaceutical Solids (Marcel Dekker, New York, 1999), pp. 279-330
27. S.Y. Yang, G.H. Du, Y. Lu, J. Mol. Struct. 1095, 79-86 (2015)
28. M. Li, H.J. Wang, D.M. Wu, Nat. Prod. Res. Dev. 19, 374-378 (2007)
29. J.W. da Cruz, L.R. de Moraes, M.H. dos Santos, G.A. da Silva, M.R.P.L. Brigagão, J. Ellena, A.C. Doriguetto, Helv. Chim. Acta 91, 144-154 (2008)
30. M.A. Spackman, D. Jayatilaka, Cryst. Eng. Comm. 11, 19-32 (2009)
31. N.B. Gong, Y. Wang, B.X. Zhang, D.Z. Yang, G.H. Du, Y. Lu, Steroids 143, 18-24 (2019)
32. G.P. Stahly, Cryst. Grow. Des. 7, 1007-1026 (2007) |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
